- Nanobiotix (NBTX, Financial) to present full results from Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer at ESTRO 2025.
- Study conducted at MD Anderson Cancer Center focusing on advanced pancreatic cancer patients.
- Post-presentation, a conference call led by CEO Laurent Levy will be held on May 5th.
Nanobiotix (Euronext: NANO, NASDAQ: NBTX), a late-stage clinical biotechnology company, has announced the presentation of complete results from their Phase 1 study involving JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The pivotal findings will be showcased at the European Society for Radiotherapy and Oncology's annual meeting (ESTRO 2025) on May 4th at 11:00 AM EDT, led by Principal Investigator Dr. Eugene Koay from The University of Texas MD Anderson Cancer Center.
The Phase 1 study, focusing on the challenging domain of pancreatic cancer treatments, comprised dose escalation and dose expansion components. This suggests progress in establishing a safety profile and identifying a recommended Phase 2 dose. The innovative nanoparticle-based therapy, activated by radiotherapy, aims to improve radiation effects on tumor cells, representing a potential breakthrough in oncology treatment options.
In conjunction with the presentation, Nanobiotix will host a conference call and webcast on May 5th at 8:00 AM EDT to delve into the findings, guided by CEO Laurent Levy. Participants can engage via webcast, audio-only dial-in, and are encouraged to submit questions in advance to [email protected].
This development marks a significant milestone for Nanobiotix, as they continue to pioneer in nanoparticle therapeutics, potentially enhancing treatment strategies for hard-to-treat cancers like pancreatic cancer.
